SIGN UP
SIGN UP TO LEARN MORE
Largely unaddressed inflammation and fibrosis may be damaging your patients' kidneys. However, new discoveries about chronic kidney disease and type 2 diabetes are well underway.1-6
Sign up below for updates on CKD and T2D, inflammation and fibrosis, and news from Bayer.
Guidance for the local markets:
Your local sign-up specifications and connect to consent system need to be implemented during the local rollout process by utilizing the BCU (Bayer Connected Universe) feature.
The purpose of this sign-up is to provide a registration process which can also collect consent to enable your local electronic HCP communication. To learn more about the BCU availability in your country or to include your local 3rd party HCP verification provider in the BCU, please contact the Website Factory team at baywsf.com or raise a support ticket via support.baywsf.com.
CKD: chronic kidney disease; T2D: type 2 diabetes.
References:
- Tesch GH, et al. Front Pharmacol. 2017;8. doi:10.3389/fphar.2017.00313. Return to content
- Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
- Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
- Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
- Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content
- Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010. Return to content